Pulling SEC filings + quote and writing the call…

Fortress Biotech, Inc.
Next earnings Aug 12, 2026 · consensus $-0.20 EPS, $18.7M rev
Last earnings +3.1% on 2026-05-14
Revenue grew 9.7% YoY.
Fortress Biotech, Inc. shows $63.3M in FY2025 revenue (+9.7% YoY), a 10.8% net margin, and 13.7% ROE.
Sources: SEC EDGAR (CIK 0001429260, latest 10-Q filed 2026-05-14) · as of 6/26/2026, 6:34:27 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Gross profit | — | — | — | — | — |
| Operating income | -$189M | -$204M | -$142M | -$110M | -$70.2M |
| Net income | -$64.7M | -$86.6M | -$60.6M | -$46.0M | $6.82M |
| Diluted EPS | -$0.79 | -$15.97 | -$8.47 | -$2.69 | -$0.07 |
| Net margin | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1047 tracked peers · median
| 2026-06-22 | Jin David Chief Financial Officer | Award | 400K | |
| 2026-04-01 | Jin David Chief Financial Officer | Award | 2.97K @ $2.18 | $6.46K |
| 2026-03-18 | ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN | Award | 475K | |
| 2026-03-18 | WEISS MICHAEL S Executive Vice Chairman | Award | 475K | |
| 2026-01-02 | Fortress Biotech, Inc. 10% owner | Award | 111K | |
| 2026-01-01 | Klein Dov Director | Award | 27.3K | |
| 2026-01-01 | Harvey Jimmie Director | Award | 27.3K | |
| 2026-01-01 | Lorenz Kevin Director | Award | 27.3K |